Literature DB >> 28787318

Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness.

Daisuke Kamimura1, Takeki Suzuki, Anna L Furniss, Michael E Griswold, Iftikhar J Kullo, Merry L Lindsey, Michael D Winniford, Kenneth R Butler, Thomas H Mosley, Michael E Hall.   

Abstract

AIM: Osteoprotegerin (OPG) is associated with a poor prognosis in patients with heart failure with preserved ejection fraction (HFpEF). OPG has also been associated with fibrosis and collagen cross-linking, which increase arterial and left ventricle (LV) myocardial stiffness. Little is known about the relation of OPG and LV structure and function in African-Americans who are disproportionately affected by HFpEF. METHODS AND
RESULTS: Our analysis included 1172 participants with preserved LV ejection fraction (>50%) from the African-American cohort in the Genetic Epidemiology Network of Arteriopathy Study (mean age 63 years, 72% female). We used diastolic wall strain indicator measured by echocardiography to assess LV myocardial stiffness. Diastolic wall strain was calculated as (LV posterior thickness at end-systole - LV posterior thickness at end-diastole)/LV posterior thickness at end-systole. Associations between OPG levels and indices of arterial and LV structure and function were evaluated by using generalized linear mixed models and adjusted for possible confounders. OPG levels were correlated with age, female sex, presence of hypertension and diabetes, and lower estimated glomerular filtration rate (P < 0.05 for all). Multivariable analysis revealed that higher OPG levels were associated with greater LV mass index, increased LV myocardial stiffness, and higher N-terminal prohormone brain natriuretic peptide levels (P < 0.05 for all).
CONCLUSION: In African-Americans, higher OPG levels were associated with characteristics common in patients with HFpEF and were significantly associated with known precursors to HFpEF. These findings indicate a potential role for OPG in the pathophysiology of HFpEF in African-Americans.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28787318      PMCID: PMC6100745          DOI: 10.2459/JCM.0000000000000549

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  51 in total

1.  Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.

Authors:  Michael R Zile; John S Gottdiener; Scott J Hetzel; John J McMurray; Michel Komajda; Robert McKelvie; Catalin F Baicu; Barry M Massie; Peter E Carson
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

Review 2.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

3.  The HFpEF Obesity Phenotype: The Elephant in the Room.

Authors:  Dalane W Kitzman; Sanjiv J Shah
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

4.  Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.

Authors:  Thor Ueland; Arne Yndestad; Erik Øie; Geir Florholmen; Bente Halvorsen; Stig S Frøland; Svein Simonsen; Geir Christensen; Lars Gullestad; Pål Aukrust
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

Review 5.  Arterial stiffness in diabetes mellitus.

Authors:  Stuart B Prenner; Julio A Chirinos
Journal:  Atherosclerosis       Date:  2014-12-20       Impact factor: 5.162

6.  Is increased arterial stiffness a cause or consequence of atherosclerosis?

Authors:  Laura Hansen; W Robert Taylor
Journal:  Atherosclerosis       Date:  2016-04-21       Impact factor: 5.162

7.  Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study.

Authors:  Deepak K Gupta; Amil M Shah; Davide Castagno; Madoka Takeuchi; Laura R Loehr; Ervin R Fox; Kenneth R Butler; Thomas H Mosley; Dalane W Kitzman; Scott D Solomon
Journal:  JACC Heart Fail       Date:  2013-04       Impact factor: 12.035

8.  Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

Authors:  Simone H Mangan; Ann Van Campenhout; Catherine Rush; Jonathan Golledge
Journal:  Cardiovasc Res       Date:  2007-08-02       Impact factor: 10.787

9.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

10.  Racial differences in the outcomes of patients with diastolic heart failure.

Authors:  Mark A East; Eric D Peterson; Linda K Shaw; Wendy A Gattis; Christopher M O'Connor
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  1 in total

1.  Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study.

Authors:  Adebamike A Oshunbade; Seth T Lirette; B Gwen Windham; Tariq Shafi; Arsalan Hamid; Semiu O Gbadamosi; Adrienne Tin; Wondwosen K Yimer; Martin Tibuakuu; Donald Clark; Daisuke Kamimura; Elizabeth A Lutz; Robert J Mentz; Ervin R Fox; Javed Butler; Kenneth R Butler; Vesna D Garovic; Stephen T Turner; Thomas H Mosley; Michael E Hall
Journal:  Mayo Clin Proc       Date:  2021-09-24       Impact factor: 11.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.